VENUS CONCEPT INC (VERO)
US92332W2044 - Common Stock
Taking everything into account, VERO scores 1 out of 10 in our fundamental rating. VERO was compared to 188 industry peers in the Health Care Equipment & Supplies industry. VERO has a bad profitability rating. Also its financial health evaluation is rather negative. VERO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
VERO had negative earnings in the past year.
VERO had a negative operating cash flow in the past year.
VERO had negative earnings in each of the past 5 years.
VERO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VERO's Return On Assets of -62.61% is on the low side compared to the rest of the industry. VERO is outperformed by 74.33% of its industry peers.
The Return On Equity of VERO (-1348.76%) is worse than 89.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.61% | ||
| ROE | -1348.76% | ||
| ROIC | N/A |
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 68.40%, VERO is in the better half of the industry, outperforming 78.07% of the companies in the same industry.
VERO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for VERO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
2. Health
2.1 Basic Checks
VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERO has been increased compared to 1 year ago.
The number of shares outstanding for VERO has been increased compared to 5 years ago.
The debt/assets ratio for VERO is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.94, we must say that VERO is in the distress zone and has some risk of bankruptcy.
VERO's Altman-Z score of -4.94 is on the low side compared to the rest of the industry. VERO is outperformed by 70.59% of its industry peers.
A Debt/Equity ratio of 12.07 is on the high side and indicates that VERO has dependencies on debt financing.
VERO has a Debt to Equity ratio of 12.07. This is amonst the worse of the industry: VERO underperforms 90.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 12.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.94 |
ROIC/WACCN/A
WACC5.02%
2.3 Liquidity
VERO has a Current Ratio of 1.99. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
VERO has a Current ratio of 1.99. This is in the lower half of the industry: VERO underperforms 70.05% of its industry peers.
VERO has a Quick Ratio of 1.30. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
VERO has a Quick ratio of 1.30. This is in the lower half of the industry: VERO underperforms 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.3 |
3. Growth
3.1 Past
VERO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.56%.
VERO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.24%.
Measured over the past years, VERO shows a very strong growth in Revenue. The Revenue has been growing by 28.26% on average per year.
EPS 1Y (TTM)2.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.93%
Revenue 1Y (TTM)-19.24%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-17.4%
3.2 Future
VERO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.06% yearly.
VERO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.14% yearly.
EPS Next Y-2.82%
EPS Next 2Y28.89%
EPS Next 3Y22.06%
EPS Next 5YN/A
Revenue Next Year-13.52%
Revenue Next 2Y-3.55%
Revenue Next 3Y-0.14%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
VERO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VERO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VERO's earnings are expected to grow with 22.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.89%
EPS Next 3Y22.06%
5. Dividend
5.1 Amount
No dividends for VERO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VENUS CONCEPT INC
NASDAQ:VERO (11/4/2024, 8:00:02 PM)
After market: 0.403 -0.03 (-7.06%)0.4336
+0 (+0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.15M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.61% | ||
| ROE | -1348.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.4% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 12.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)2.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-2.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.24%
Revenue growth 3Y-0.71%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y